Top

Published in:

Open Access 01-12-2018 | Research

Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals

Authors: Wei Zhai, Saiyang Li, Jin Zhang, Yonghui Chen, Junjie Ma, Wen Kong, Dongkui Gong, Junhua Zheng, Wei Xue, Yunfei Xu

Published in: Molecular Cancer | Issue 1/2018

Abstract

Purpose

Although microRNAs (miRNAs) were revealed as crucial modulators in tumor metastasis and target therapy, our understanding of their roles in metastatic renal cell carcinoma (mRCC) and Sunitinib treatment was limited. Here we sought to identify human miRNAs that acted as key regulators in renal cancer metastasis and Sunitinib treatment.

Experimental design

We focused on 2 published microarray data to select out our anchored miRNA and then explored the roles of miR-452-5p both in vitro and in vivo, which was downregulated after Sunitinib treatment while upregulated in metastasis renal cell carcinoma (RCC) tissues.

Results

Here, we discovered that treating with Sunitinib, the targeted receptor tyrosine kinase inhibitor (TKI), inhibited renal cancer cell migration and invasion via attenuating the expression of miR-452-5p. The novel identified miR-452-5p was upregulated and associated with poor prognosis in RCC. Preclinical studies using multiple RCC cells and xenografts model illustrated that miR-452-5p could promote RCC cell migration and invasion in vitro and in vivo. Mechanistically, P65 could directly bind to the miR-452-5p promoter and thus transcriptionally induce miR-452-5p expression, which led to post-transcriptionally abrogate SMAD4 expression, thus inhibition of its downstream gene SMAD7.

Conclusion

Our study presented a road map for targeting this newly identified miR-452-5p and its SMAD4/SMAD7 signals pathway, which imparted a new potential therapeutic strategy for mRCC treatment.

Available only for authorised users

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.CrossRef

Chen C, Xue S, Zhang J, Chen W, Gong D, Zheng J, Ma J, Xue W, Chen Y, Zhai W, Zheng J. DNA-methylation-mediated repression of miR-766-3p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma. Int J Cancer. 2017;141:1867–78. https://doi.org/10.1002/ijc.30853.CrossRefPubMed

Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anti-Cancer Drugs. 2013;24:535–54. https://doi.org/10.1097/CAD.0b013e3283609ec1.CrossRefPubMed

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–24. https://doi.org/10.1016/j.eururo.2015.01.005.CrossRef

Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35:3–11. https://doi.org/10.1055/s-0034-1397344.CrossRefPubMedPubMedCentral

Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14. https://doi.org/10.1016/j.addr.2015.05.001.CrossRefPubMedPubMedCentral

Tan W, Liu B, Qu S, Liang G, Luo W, Gong C. MicroRNAs and cancer: key paradigms in molecular therapy. Oncol Lett. 2018;15:2735–42. https://doi.org/10.3892/ol.2017.7638. CrossRefPubMed

Drusco A, Croce CM. MicroRNAs and Cancer: a long story for short RNAs. Adv Cancer Res. 2017;135:1–24. https://doi.org/10.1016/bs.acr.2017.06.005.CrossRefPubMed

10.

Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, Lobie PE, Zhu T. c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem. 2013;288:18121–33. https://doi.org/10.1074/jbc.M113.478560.CrossRefPubMedPubMedCentral

11.

Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, et al. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res. 2014;20:2617–30. https://doi.org/10.1158/1078-0432.CCR-13-3224.CrossRefPubMed

12.

Lei L, Huang Y, Gong W. miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep. 2013;30:2897–902. https://doi.org/10.3892/or.2013.2755.CrossRefPubMed

13.

Li W, Liu M, Feng Y, Xu YF, Huang YF, Che JP, Wang GC, Yao XD, Zheng JH. Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the Nin one binding protein (NOB1). Br J Cancer. 2014;111:1188–200. https://doi.org/10.1038/bjc.2014.382.CrossRefPubMedPubMedCentral

14.

Li RZ, Wang LM. Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma. World J Surg Oncol. 2016;14:150. https://doi.org/10.1186/s12957-016-0900-y.CrossRefPubMedPubMedCentral

15.

Hu Q, Chen WX, Zhong SL, Zhang JY, Ma TF, Ji H, Lv MM, Tang JH, Zhao JH. MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. Tumour Biol. 2014;35:6327–34. https://doi.org/10.1007/s13277-014-1834-z.CrossRefPubMed

16.

Zhang Y, Han L, Pang J, Wang Y, Feng F, Jiang Q. Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis. Tumour Biol. 2016;37:8259–70. https://doi.org/10.1007/s13277-015-4725-z.CrossRefPubMed

17.

Zheng Q, Sheng Q, Jiang C, Shu J, Chen J, Nie Z, Lv Z, Zhang Y. MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B. Mol Cell Biochem. 2014;389:187–95. https://doi.org/10.1007/s11010-013-1940-z.CrossRefPubMed

18.

Goto Y, Kojima S, Kurozumi A, Kato M, Okato A, Matsushita R, Ichikawa T, Seki N. Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer. Br J Cancer. 2016;114:1135–44. https://doi.org/10.1038/bjc.2016.95.CrossRefPubMedPubMedCentral

19.

Da SR, Gustafson D, Nogueira L, Werahera PN, Molina WR, Kim FJ. Targeted therapy for metastatic renal carcinoma: an update. J Kidney Cancer VHL. 2014;1:63–73. https://doi.org/10.15586/jkcvhl.2014.14.CrossRef

20.

Mattei J, Da SR, Sehrt D, Molina WR, Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Lett. 2014;343:156–60. https://doi.org/10.1016/j.canlet.2013.09.038.CrossRefPubMed

21.

Conti A, Santoni M, Amantini C, Burattini L, Berardi R, Santoni G, Cascinu S, Muzzonigro G. Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int. 2013;2013:419176. https://doi.org/10.1155/2013/419176.CrossRefPubMedPubMedCentral

22.

Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, Rini BI. A phase II study of intermittent Sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2017;35:1764–9. https://doi.org/10.1200/JCO.2016.71.1184.CrossRefPubMed

23.

Parekh H, Rini BI. Emerging therapeutic approaches in renal cell carcinoma. Expert Rev Anticancer Ther. 2015;15:1305–14. https://doi.org/10.1586/14737140.2015.1090315.CrossRefPubMed

24.

Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, Lin W, Huang Q, Li G, Zheng J, Chang C. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ. 2017;24:1502–17. https://doi.org/10.1038/cdd.2017.74.CrossRefPubMedPubMedCentral

25.

Wang M, Sun Y, Xu J, Lu J, Wang K, Yang DR, Yang G, Li G, Chang C. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/met signaling. Int J Cancer. 2018. https://doi.org/10.1002/ijc.31289.CrossRef

26.

Vermeulen L, De Wilde G, Notebaert S, Vanden BW, Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol. 2002;64:963–70.CrossRef

27.

Sun B, Chen L, Fu H, Guo L, Guo H, Zhang N. Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-kappaB pathway contributes to the metastasis of renal cell carcinoma. Tumour Biol. 2016;37:4457–66. https://doi.org/10.1007/s13277-015-4296-z.CrossRefPubMed

28.

Meng XM, Huang XR, Xiao J, Chung AC, Qin W, Chen HY, Lan HY. Disruption of Smad4 impairs TGF-beta/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int. 2012;81:266–79. https://doi.org/10.1038/ki.2011.327.CrossRefPubMed

29.

Hu Q, Gong JP, Li J, Zhong SL, Chen WX, Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH, Tang JH. Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev. 2014;15:5137–42.CrossRef

30.

Rezapour S, Bahrami T, Hashemzadeh S, Estiar MA, Nemati M, Ravanbakhsh R, Feizi MA, Kafil HS, Pouladi N, Ghojazadeh M, Sakhinia E. STC1 and NF-kappaB p65 (Rel A) is constitutively activated in colorectal Cancer. Clin Lab. 2016;62:463–9.CrossRef

31.

Ku T, Li B, Gao R, Zhang Y, Yan W, Ji X, Li G, Sang N. NF-kappaB-regulated microRNA-574-5p underlies synaptic and cognitive impairment in response to atmospheric PM2.5 aspiration. Part Fibre Toxicol. 2017;14:34. https://doi.org/10.1186/s12989-017-0215-3. CrossRefPubMedPubMedCentral

32.

de la Rica L, Garcia-Gomez A, Comet NR, Rodriguez-Ubreva J, Ciudad L, Vento-Tormo R, Company C, Alvarez-Errico D, Garcia M, Gomez-Vaquero C, Ballestar E. NF-kappaB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation. Genome Biol. 2015;16:2. https://doi.org/10.1186/s13059-014-0561-5. CrossRefPubMedPubMedCentral

33.

Zhou R, Hu G, Liu J, Gong AY, Drescher KM, Chen XM. NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathog. 2009;5:e1000681. https://doi.org/10.1371/journal.ppat.1000681.CrossRefPubMedPubMedCentral

34.

Yang D, Sun C, Zhang J, Lin S, Zhao L, Wang L, Lin R, Lv J, Xin S. Proliferation of vascular smooth muscle cells under inflammation is regulated by NF-kappaB p65/microRNA-17/RB pathway activation. Int J Mol Med. 2018;41:43–50. https://doi.org/10.3892/ijmm.2017.3212. CrossRefPubMed

35.

Li J, Wang K, Chen X, Meng H, Song M, Wang Y, Xu X, Bai Y. Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol Biol. 2012;13:4. https://doi.org/10.1186/1471-2199-13-4.CrossRefPubMedPubMedCentral

36.

Li Y, Dai D, Lu Q, Fei M, Li M, Wu X. Sirt2 suppresses glioma cell growth through targeting NF-kappaB-miR-21 axis. Biochem Biophys Res Commun. 2013;441:661–7. https://doi.org/10.1016/j.bbrc.2013.10.077.CrossRefPubMed

37.

Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111–23. https://doi.org/10.7150/ijbs.23230.CrossRefPubMedPubMedCentral

38.

Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun. 2003;306:799–804.CrossRef

39.

Mao S, Lu G, Lan X, Yuan C, Jiang W, Chen Y, Jin X, Xia Q. Valproic acid inhibits epithelialmesenchymal transition in renal cell carcinoma by decreasing SMAD4 expression. Mol Med Rep. 2017;16:6190–9. https://doi.org/10.3892/mmr.2017.7394.CrossRefPubMed

40.

Xia X, Wu W, Huang C, Cen G, Jiang T, Cao J, Huang K, Qiu. SMAD4 and its role in pancreatic cancer. Tumour Biol 2015, 36:111–119. doi: https://doi.org/10.1007/s13277-014-2883-z. CrossRef

41.

Izumi S, Nakamura S, Mano S, Akaki S. Well differentiation and intact Smad4 expression are specific features of groove pancreatic ductal adenocarcinomas. Pancreas. 2015;44:394–400. https://doi.org/10.1097/MPA.0000000000000260. CrossRefPubMed

42.

Liu Y, Xu Y, Li X, Chen Z. Smad4 suppresses the progression of renal cell carcinoma via the activation of forkhead box protein H1. Mol Med Rep. 2015;11:2717–22. https://doi.org/10.3892/mmr.2014.3061.CrossRefPubMed

43.

Wang JY, Gao YB, Zhang N, Zou DW, Wang P, Zhu ZY, Li JY, Zhou SN, Wang SC, Wang YY, Yang JK. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol. 2014;392:163–72. https://doi.org/10.1016/j.mce.2014.05.018.CrossRefPubMed

44.

Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene. 2012;31:5162–71. https://doi.org/10.1038/onc.2012.11.CrossRefPubMedPubMedCentral

45.

Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58:629–41. https://doi.org/10.1002/hep.26369.CrossRefPubMed

46.

Passadouro M, Pedroso DLM, Faneca H. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer. Int J Nanomedicine. 2014;9:3203–17. https://doi.org/10.2147/IJN.S64456.CrossRefPubMedPubMedCentral

47.

Goto Y, Kurozumi A, Nohata N, Kojima S, Matsushita R, Yoshino H, Yamazaki K, Ishida Y, Ichikawa T, Naya Y, Seki N. The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma. Oncotarget. 2016;7:59070–86. https://doi.org/10.18632/oncotarget.10887.CrossRefPubMedPubMedCentral

48.

Khella H, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, Dharsee M, Latif A, Pasic MD, Lianidou E, et al. miR-221/222 are involved in response to Sunitinib treatment in metastatic renal cell carcinoma. Mol Ther. 2015;23:1748–58. https://doi.org/10.1038/mt.2015.129.CrossRefPubMedPubMedCentral

49.

Cunha PP, Costa PM, Morais CM, Lopes IR, Cardoso AM, Cardoso AL, Mano M, Jurado AS, Pedroso DLM. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors. Hum Mol Genet. 2017;26:4375–87. https://doi.org/10.1093/hmg/ddx323.CrossRefPubMed

50.

Shin HW, Cho CH, Kim TY, Park JW. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. Biochem Biophys Res Commun. 2010;398:205–11. https://doi.org/10.1016/j.bbrc.2010.06.060.CrossRefPubMed

Title: Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals
Authors: Wei Zhai
Saiyang Li
Jin Zhang
Yonghui Chen
Junjie Ma
Wen Kong
Dongkui Gong
Junhua Zheng
Wei Xue
Yunfei Xu
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2018
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-018-0906-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Experimental design

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling

miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer

Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer

Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia

MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47

The pro-metastasis effect of circANKS1B in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer